Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C

OBJECTIVES: : Novel treatments for hepatitis C demonstrate high cure rates, but current high prices can be a barrier to rapid global treatment scale-up. Generic competition can rapidly lower drug prices. Using data on exports of raw materials in 2015, we calculated currently feasible generic prices...

Descripción completa

Detalles Bibliográficos
Autores principales: Hill, Andrew, Simmons, Bryony, Gotham, Dzintars, Fortunak, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mediscript Ltd 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946692/
https://www.ncbi.nlm.nih.gov/pubmed/27482432

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946692/
https://www.ncbi.nlm.nih.gov/pubmed/27482432

Ejemplares similares